MYLAN-PANTOPRAZOLE TABLET (DELAYED-RELEASE)

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE)

Dostupno od:

MYLAN PHARMACEUTICALS ULC

ATC koda:

A02BC02

INN (International ime):

PANTOPRAZOLE

Doziranje:

40MG

Farmaceutski oblik:

TABLET (DELAYED-RELEASE)

Sastav:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 40MG

Administracija rute:

ORAL

Jedinice u paketu:

100/500

Tip recepta:

Prescription

Područje terapije:

PROTON-PUMP INHIBITORS

Proizvod sažetak:

Active ingredient group (AIG) number: 0133229001; AHFS:

Status autorizacije:

CANCELLED POST MARKET

Datum autorizacije:

2018-07-12

Svojstava lijeka

MYLAN-PANTOPRAZOLE (pantoprazole sodium)
1 of 37
PRODUCT MONOGRAPH
PR
MYLAN-PANTOPRAZOLE
Pantoprazole sodium enteric-coated tablets
40 mg pantoprazole (as pantoprazole sodium sesquihydrate)
H
+
, K
+
-ATPase Inhibitor
Mylan Pharmaceuticals ULC
85 Advance Rd.
Etobicoke, Ontario
M8Z 2S6
Submission Control Number: 211159
Date of Revision: December 14, 2017
MYLAN-PANTOPRAZOLE (pantoprazole sodium)
2 of 37
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
7
DRUG INTERACTIONS
...............................................................................................................
11
DOSAGE AND ADMINISTRATION
..........................................................................................
13
OVERDOSAGE
..............................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
15
STORAGE AND STABILITY
......................................................................................................
17
SPECIAL HANDLING INSTRUCTIONS
...................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 17
PART II: SCIENTIFIC INFORMATION
..............